Navigation Links
$37 million financing for company based on macular degeneration research
Date:10/9/2007

arily pleased to have these discoveries so rapidly and substantially supported as they are translated into valuable diagnostics, said John Puziss, Director of Technology Licensing for Yales Office of Cooperative Research. We also want to thank the Sackler Fund for the Arts and Sciences and Raymond and Beverly Sackler, long standing supporters of medical research and the Yale School of Medicine, for the grant that funded this landmark research and the Verto Institute founded and directed by Jonathan and Richard Sackler that continues to fund Dr. Hohs projects in ophthalmology and other diseases.

Colin J. Foster, Optherions President and CEO, said, We are embarking on a program that exploits a new and exciting area of research with breakthrough potential in areas of high unmet medical need. Foster is the former CEO of Bayer Pharmaceuticals in the U.S. and Region Head for Bayer Pharmaceuticals in North America.

Among the sources of capital for the financing are: Quaker BioVentures, Philadelphia; Domain Associates, Princeton, NJ and San Diego; Johnson & Johnson Development Corporation, New Brunswick, NJ; Purdue Pharmaceutical Products L.P., Stamford, CT; Pappas Ventures, Research Triangle Park, NC; Biogen Idec New Ventures, Cambridge, MA and GE Healthcare Financial Services, Chicago, IL.

The successful completion of this Series A financing will enable the company to advance the work of Dr. Hageman, Dr. Hoh and others, and hopefully transform the diagnosis and treatment of dry age-related macular degeneration, said David Scheer, Chairman of the Optherion Board of Directors.


'/>"/>

Contact: Janet Rettig Emanuel
janet.emanuel@yale.edu
203-432-2157
Yale University
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Hundred million dollar gift for malaria institute
3. George Bush pledges 200 million dollars for AIDS relief
4. Hope for 11 million children facing death from illnesses
5. The forgotten epidemic killing millions
6. WHO and UNAIDS unveil plan to get 3 million AIDS patients on treatment by 2005
7. Over Six Million HIV Infected People In South Africa- Finds A Survey
8. Tanzanian Government Sanctions $20 Million For AIDS Arug
9. Grant of $7 million for Orissa Medical College from Japan
10. Merck to pay $ 253.5 million to Vioxx victim family
11. GlaxoSmithKline to Supply United States with 8 Million flu vaccine, Fluarix
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...an farm, FDA announces , , FRIDAY, July...ering the first big clue in the nationwide salmone...ay that tainted jalapeno peppers had been definiti...d and Drug Administration gave the all-clear to ja...tes, but warned consumers to avoid any raw jalapen...
(Date:7/25/2008)...ter & Olsen LLP has filed a,class action lawsuit a...,"Company") (Nasdaq: ARTC ) and certain of its of...District of Texas on behalf of all persons or,enti...m January 24, 2008,through July 18, 2008 (the "Com... or entities who purchased call options or sold pu...
(Date:7/25/2008)...inancial results -, LAVAL, QC, July 25 /PRNewswir...DSS) today announced that it will host a conferenc...scuss its second quarter 2008,financial results. L...cial,results via news release at approximately 7:0...ll by telephone, dial 416-646-3095 or,1-800-814-48...
(Date:7/25/2008)...FirstCall/ -- Thoratec,Corporation (Nasdaq: THOR ...atory support therapies to save, support and resto...port its operating results for the second,quarter ...uly 31., The company will hold a conference call ...ivities to all interested parties at 1:30 p.m.,Pa...
Breaking Medicine News(10 mins):Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2
...rnment is likely to invoke the compulsory licensin...ble domestic drug //firms to produce and stockpile...seful in combating the global threat against the m... 92 empowers the government to issue CL without re...
...l wall hernias are one of the most common conditio...,000 repairs// performed annually. Although ventra...rences and complications remain a vexing problem. ... consistent risk factor for recurrence after VHR. ...
...Paxton and Colleagues from University of Amsterdam...nt transmission of HIV infection to child. Though ...on of HIV accounts for a large proportion of HIV i...sult of breastfeeding, which requires transfer of ...
... cancer patient made the journey from London to In...cation-Herceptin.// India is likely to attract mo...ving both for surgical procedures and medication.F...ate hospital in Pune for a mastectomy and reconstr...
Other Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Breast feeding can prevent HIV infection transmission 2
(Date:7/24/2008)...l/ -- MacroChem Corporation (OTC,Bulletin Board: M... trial,involving 37 patients who completed a 48-we...ety study of EcoNail, a topical antifungal,lacquer... The composite,primary efficacy endpoint of the tr...gy (negative fungal culture and negative KOH) and ...
(Date:7/23/2008)...uly print edition of Clinical ...23 /- A Roche Diagnostics-sponsored,p...type natriuretic peptide,(NT-proBNP) confirms the ...on in predicting the risk of cardiovascular advers...oidal anti-inflammatory drugs of,the COX inhibitor...
(Date:7/23/2008)...Pharma Inc., a company developing,breakthrough mol...mography,(PET) market, announced positive Phase I ...racer for myocardial perfusion imaging. BFPET is,F...plete Phase I clinical,development., BFPET is a P...w in the,heart (myocardial perfusion). Myocardial ...
(Date:7/23/2008).../ -- Dendreon Corporation,(Nasdaq: DNDN ) today a...toring Committee (IDMC) to review in October 2008 ...to the Company,s Phase 3 IMPACT (IMmunotherapy,for...D9902B) clinical trial,of PROVENGE(R) (sipuleucel-...ve cellular immunotherapy for the treatment of adv...
Breaking Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 1Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 2Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 3Study Finds PCI Safe Effective Despite Off Site Cardiac Surgery 1620 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 1Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 2Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 3Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 4Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 5Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 6Study Results Show Investigational Drug Prasugrel Cuts Risk of Stent Related Clots by More than Half Versus Clopidogrel 1617 7New Drug Shows Promise in Use With Coronary Stents 15457 1New Drug Shows Promise in Use With Coronary Stents 15457 2Motorola Biometric Identification System Selected by West Virginia State Police 2660 1Motorola Biometric Identification System Selected by West Virginia State Police 2660 2
...Serial Outpatient Infusion Study in Patients with,...he American,College of Cardiology 56th Annual Scie...RLEANS, March 25, 2007,/PRNewswire/ -- Scios Inc. ...Phase 2 study of nesiritide (NATRECOR(R)) showed a...te of death and,cardiorenal hospitalization at 12 ...
....J., March 25, 2007 /PRNewswire/ -- Once-daily,dos...tolvaptan, a,vasopressin receptor antagonist, was ... of acutely decompensated heart failure (ADHF),in ... without an,adverse effect on their long-term surv...ort- and long-term analyses of the,international l...
Other Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 2Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 3Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 4Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 5Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 6Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials 7
Smooth colibri tip; In Titanium.
Fine .12mm Tip With 5mm Platform; In Titanium.
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium.
0.3mm tips; 9.5mm from tips to cross action; in Titanium.
Medicine Products: